Duloxetine is licensed for which of the following conditions?

• A. Diabetic peripheral neuropathy pain
• B. Fibromyalgia
• C. Migraine prophylaxis
• D. Osteoarthritis

Answer: (A)

Duloxetine’s licensed use reflects its approved role as a serotonin-norepinephrine reuptake inhibitor that helps modulate pain signaling, particularly in chronic neuropathic and musculoskeletal pain. For diabetic peripheral neuropathy pain, robust trial evidence led regulators to approve this indication, so it is the recognized licensed use in this context.

Although duloxetine can be effective for other conditions such as fibromyalgia, migraine prophylaxis, and osteoarthritis in some regions or guidelines, the licensing status varies by regulatory authority. In this scenario, the condition for which duloxetine is officially licensed is diabetic peripheral neuropathy pain, making it the correct choice.